Clinical trials: Zoledronic acid
Use of Zoledronic Acid in Breast Cancer
Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
The investigators will involve about 25 Patients of postmenopausal women who have ER/PR positive early breast cancer in each arm. The study is a two-arm comparative, prospective, interventional, and randomized study.
- Trial name
- NCT05164952
- Testing
- Zoledronic Acid 4 MG
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Non-Small Cell Lung Cancer
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT01951586
- Testing
- Denosumab, Zoledronic acid, Standard Chemotherapy
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Amgen
Metastatic Renal Cell Carcinoma
Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
Multicenter, randomized, open-label, 2-arm, parallel-group, phase III study whose goal is to assess the efficacy and safety profile of bone-targeted treatments (Arm A: denosumab or zoledronic acid) versus the control arm (Arm B…
- Trial name
- MOSCAR (NCT03408652)
- Testing
- denosumab
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Leon Berard
Osteoporosis
Efficacy of Zoledronic Acid in Osteoporosis
There has been no comparative data between Zoledronic acid and Zoledronic acid combined with active vitamin D in primary and secondary osteoporosis.
- Trial name
- NCT03183557
- Testing
- "Zoledronic acid", "Reclast®", "Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®"
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Shinshu University
Breast Cancer
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
Triple-negative breast cancer has a poor prognosis and lacks effective adjuvant treatment. A number of preclinical and clinical trials have shown that bisphosphonates have direct or indirect anti-tumor activity, and early use of…
- Trial name
- NCT04045522
- Testing
- Zoledronic Acid
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Shengjing Hospital
Breast Cancer
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer.
- Trial name
- NCT00127205
- Testing
- clodronate disodium, ibandronate sodium, zoledronic acid
- Volunteers
- 6,097 people
- Sponsor
- SWOG Cancer Research Network
Osteogenesis Imperfecta
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o.
- Trial name
- NCT01679080
- Testing
- Zoledronic acid, Teriparatide, No active treatment
- Where
- 3 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- University of Aarhus
Postmenopausal Osteoporosis
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
The recommended dosing regimen of zoledronic acid in Chinese osteoporosis patients is completely in accordance with the one of 5 mg per year abroad that based on the dosing regimen in Paget's disease.
- Trial name
- NCT04719650
- Testing
- Zoledronic Acid Injection
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Breast Neoplasms, Bone Loss
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients.
- Trial name
- BLAZE (NCT01623908)
- Testing
- Zoledronate
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Multiple Myeloma
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to…
- Trial name
- Z-MARK (NCT00622505)
- Testing
- zoledronic acid
- Where
- 42 sites in United States
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of the Bone
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and…
- Trial name
- NCT00740129
- Testing
- Zoledronic Acid
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Bariatric Surgery Candidate
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
- Trial name
- NCT03424239
- Testing
- Zoledronic Acid, Calcium citrate + vitamin D, Vitamin D3
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis
Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand that prevents recruitment and differentiation of mature osteoclasts.
- Trial name
- ZOLARMAB (NCT03087851)
- Testing
- Zoledronic Acid
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Aarhus University Hospital
Postmenopausal Osteoporosis
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide.
- Trial name
- DATA-HD (NCT02176382)
- Testing
- denosumab, teriparatide, Zoledronic acid
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Prostate Cancer
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss.
- Trial name
- NCT00058188
- Testing
- cholecalciferol, calcium gluconate, zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Northwestern University
Stroke
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke Patients
In order to reduce the incidence of fractures due to osteopenia, osteoporosis, and bone mineral density in first stroke patients, the purpose of this study was to determine whether it is meaningful to administer zoledronic acid…
- Trial name
- NCT04652128
- Testing
- Zoledronic acid
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Breast Cancer, Prostate Cancer
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System.
- Conditions
- Breast Cancer, Prostate Cancer, Metastasis
- Trial name
- REaCT-BTA (NCT02721433)
- Testing
- Pamidronate, Denosumab, Zoledronate
- Where
- Canada
- Volunteers
- 263 people
- Sponsor
- Ottawa Hospital Research Institute
Osteoporosis Fracture, Spinal Cord Injuries
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
This is a randomized study to determine the effects of monthly romosozumab for one year or one-time zoledronic acid on bone mineral density (BMD) and biochemical markers of bone formation and resorption, in patients with spinal…
- Trial name
- NCT04597931
- Testing
- Romosozumab, Zoledronic Acid
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Bone Metastatic Non-small Cell Lung Cancer
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of…
- Trial name
- NCT04325776
- Testing
- AL2846, Zoledronic Acid Injection
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.